Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 39,048

Document Document Title
WO/2018/106646A1
The invention relates to triazole compounds of formula (I') or pharmaceutically acceptable salts thereof, useful as modulators of demyelinating diseases: wherein A is selected from the group consisting of (i), (ii), (iii), (iv), (v), and...  
WO/2018/107004A1
The present invention provides a method of treating a subject afflicted with cancer comprising administering to the subject an effective amount of a PP2A inhibitor.  
WO/2018/105775A1
The present invention relates to an indazole compound and an organic light emitting device which exhibits superior efficiency characteristics by comprising the indazole compound in one or more organic layers.  
WO/2018/103745A1
The present invention relates to a carbazole compound and the use thereof. The compound has the following structural formula: the carbazole compound can be used for preparing an electronic device having a relatively high stability, a rel...  
WO/2018/105632A1
The present invention addresses the problem of developing and providing a novel insecticide for agricultural and horticultural use since pests still cause extensive damage on the production of agricultural and horticultural crops and pes...  
WO/2018/106459A1
The invention provides novel chemical compounds useful for treating one or more of autoimmune diseases, cancer, cardiovascular diseases, inflammatory diseases and diabetes, or a related disease or disorder thereof, and pharmaceutical com...  
WO/2018/104194A1
The invention relates to compounds of formula (1) which are suitable for use in electronic devices, and to electronic devices, in particular organic electroluminescent devices, containing said compounds.  
WO/2018/103726A1
Provided are a crystal form of a bromodomain protein inhibitor 2-[4-(2-hydroxyethoxy)-3,5-dimethylphenyl]-5,7-dimethoxyquin azolin-4(3H)-one represented by Formula I, a preparation method and a use thereof. The present invention belongs ...  
WO/2018/104474A1
The present invention relates to a compound of formula (I), and also the tautomeric forms, optical isomers and geometrical isomers thereof, the addition salts thereof with an acid or base, and/or the solvates thereof. The invention also ...  
WO/2018/104193A1
The invention relates to compounds which are suitable for use in electronic devices, and to electronic devices, in particular organic electroluminescent devices, containing said compounds.  
WO/2018/105492A1
A method for producing a compound represented by formula (1), which comprises a step wherein a compound represented by formula (2) and a compound represented by formula (3) are mixed and reacted with each other in the presence of a base.  
WO/2018/105776A1
The present invention relates to a phenanthroline compound and an organic light emitting device which exhibits excellent efficiency properties by including the same in one or more organic layers.  
WO/2018/100159A1
The present invention relates to bacterial glutaminyl cyclases and inhibitors thereof for use in the treatment of periodontitis and related conditions, and provides a bacterial glutaminyl cyclase (bacQC); an antibody which recognizes the...  
WO/2018/102453A1
Disclosed are compounds useful, for example, in methods of treating hyperproliferative disorders such as cancer, methods of arresting the cell cycle in cancer cells, methods of inhibiting glutathione synthesis in cancer cells, and associ...  
WO/2018/102067A2
The present disclosure relates to bifunctional compounds, which find utility as modulators of tau protein. In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a VHL or cereblon ligand whi...  
WO/2018/100070A1
The invention provides novel compounds having the general formula I: (I) wherein R1, R2, the A ring and the B ring are as described herein, pharmaceutical compositions including the compounds and methods of using the compounds.  
WO/2018/099846A1
The present invention relates to compounds, comprising at least one structural element with at least three fused aromatic or heteroaromatic rings (AR) and at least one structural element with an aromatic or heteroaromatic valerolactam (A...  
WO/2018/102634A1
The present invention relates to Tricyclic Heterocycle Compounds of Formula (I): and pharmaceutically acceptable salts or prodrug thereof, wherein A, X, Y, Z, R1, R7A, R7B and R8 are as defined herein. The present invention also relates ...  
WO/2018/099812A1
Compounds of formula (I), wherein the substituents are as defined in claim 1, and the agrochemically acceptable salts, stereoisomers, enantiomers, tautomers and N-oxides of those compounds, can be used as insecticides and can be prepared...  
WO/2018/101764A1
The present application relates to a heterocyclic compound represented by chemical formula 1, and an organic light-emitting element comprising the same.  
WO/2018/099814A1
The invention relates to novel pyrido-phenanthroline derivatives, to the production and use thereof in the field of medicine, in particular for cancer therapy.  
WO/2018/099146A1
Disclosed is a method for asymmetrically synthesizing aspidosperma alkaloid. In this method, a key intermediate of formula (4) is obtained by 6 steps of reactions, including [4+2] cycloaddition of the compound of formula (1a) and the com...  
WO/2018/102366A1
The invention relates to HPK1 inhibitors useful in the treatment of cancers, and other serine-threonine kinase mediated diseases, having the Formula: where A, R1, R2, R3, R4, R5, R6, R16, R17, X1, X2, X3, X4, m, and n are described herein.  
WO/2018/100029A1
The invention relates to heterocyclic compounds, particularly for use in electronic devices. The invention further relates to a method for producing the compounds according to the invention, and to electronic devices comprising same.  
WO/2018/102419A1
The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.  
WO/2018/098500A1
The present invention is directed to, in part, fused heteroaryl compounds and compositions useful for preventing and/or treating a disease or condition relating to aberrant function of a voltage-gated, sodium ion channel, for example, ab...  
WO/2018/098411A1
The disclosure generally relates to compounds of formula (I), including their salts, as well as compositions and methods of using the compounds to treat disorders associated with GSK-3.  
WO/2018/097648A1
The present application relates to a heterocyclic compound represented by chemical formula 1, and an organic light emitting element using the same.  
WO/2018/097254A1
The present invention relates to a novel production method of a triazolopyridine compound or a salt thereof, which has PHD inhibitory activity and is useful for the treatment or prophylaxis of diseases associated with decrease in the EPO...  
WO/2018/097295A1
Provided is a crystal of a novel pyrido[3, 4-d]pyrimidine derivative having excellent CDK 4/6 inhibitory activity. A crystal of a compound represented by formula (I). In the formula, R1 represents a hydrogen atom or a C1-3 alkyl group; R...  
WO/2018/097318A1
The present invention provides a tetrazolinone represented by formula (I) and a pest control agent comprising the same, and their use thereof. Formula (I) [wherein, W1 represents an oxygen atom or a sulfur atom; W2 represents a hydrogen ...  
WO/2018/096159A1
The invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereof. In addition, the present invention relates to methods of manufacturing and methods of using the compounds of formula (I) as well as pharmace...  
WO/2018/097297A1
The purpose of the present invention is to provide a compound that has excellent CDK 4/6 inhibitory activity. The present invention is a compound represented by formula (I) or a pharmaceutically acceptable salt of the compound.  
WO/2018/095398A1
The present invention relates to a pyrimido[5,4-b]indolizine or pyrimido[5,4-b]pyrrolizine compound, a preparation method and a use thereof. The compound of the present invention has good inhibitory activity on BTK both at the molecular ...  
WO/2018/098280A1
The present application provides bifunctional compounds of Formula (X): Targeting Ligand or an enantiomer, diastereomer, or stereoisomer thereof, or pharmaceutically acceptable salt, hydrate, solvate, or prodrug thereof, which act as pro...  
WO/2018/096550A1
The present invention relates to an improved process for the preparation of methyl 4,6-diamino-2-[ 1-(2-fluorobenzyl)-1 H -pyrazolo[3,4-b )pyridin-3 -yl]-5-pyrimidinyl(methyl)carbamatecompound of formula-1 and its polymorphs thereof, rep...  
WO/2018/095795A1
Polycyclic compounds of formula (I), wherein the substituents are as defined in claim 1, and the agrochemically acceptable salts, stereoisomers, enantiomers, tautomers and N-oxides of those compounds, can be used as insecticides and can ...  
WO/2018/095953A1
The invention relates to compounds of the formula (Ia) or (Ib), in which Aa, Ab, Ac, Ad, R1, R10R11, R12, R13, R14, R15, R16, R17, Q, R4, R5, R6 and n have the meanings indicated in the claims, and to agrochemical formulations containing...  
WO/2018/095426A1
Disclosed are a pyrazolo-heteroaryl derivative, a preparation method and medical use thereof. In particular, the present invention relates to a new pyrazolo-heteroaryl derivative as shown in the general formula (I), a preparation method ...  
WO/2018/091153A1
The present invention relates to novel substituted N-(3-fluoropropyl)-pyrrolidine compounds of formula (l-A): wherein R1 and R2 represent independently a hydrogen atom or a deuterium atom; A represents an oxygen or nitrogen atom; and SER...  
WO/2018/092928A1
The present invention relates to a benzonaphthyridine compound and an organic electroluminescent element comprising same in one or more organic layers and thereby exhibiting excellent efficiency properties.  
WO/2018/090939A1
Provided is a 8,9-dihydroimidazole[1,2-a]pyrimido[5,4-e]pyrimidine-5(6H)-k etone compound. In particular, provided is a compound of formula (I), or a pharmaceutically acceptable salt or prodrug thereof, wherein A and R1-R7 are as defined...  
WO/2018/094293A1
Provided herein is a kit for the determination of the absolute configuration of alcohols of a competing enantioselective conversion approach.  
WO/2018/092047A1
The present invention relates to a new compound of formula I: or pharmaceutically acceptable salt, solvate or stereoisomer thereof, wherein: V1 is C or N, V2 is C(R2) or N, whereby if V1 is C then V2 is N, if V1 is C then V2 is C(R2), or...  
WO/2018/093949A1
Provided herein are spirocyclic and fused bicyclic carbamates and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful as modulators of MAGL. Furthermore, the subject compounds and comp...  
WO/2018/092927A1
The present invention relates to a benzonaphthyridine compound and an organic electroluminescent element comprising same in one or more organic layers and thereby exhibiting excellent efficiency properties.  
WO/2018/093946A1
Provided herein are piperazine carbamates and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful as modulators of MAGL. Furthermore, the subject compounds and compositions are useful ...  
WO/2018/094362A1
The present invention is directed to certain amides and heterocyclic compounds. The present invention also relates to uses of these compounds to treat several diseases including autoimmune disorders, cardiovascular disorders, inflammatio...  
WO/2018/094134A1
The present disclosure provides compounds represented by Formula( I), and the pharmaceutically acceptable salts and solvates thereof, wherein R1a, R1b, R2a, R2b, R3, R4, R5, R6, R7, E and (B) are as defined as set forth in the specificat...  
WO/2018/090921A1
Disclosed are a class of URAT1 inhibitor compounds and the use of such compounds. These compounds are compounds represented by the structure of formula (I) or pharmaceutically acceptable salts thereof. Experiments show that the compounds...  

Matches 1 - 50 out of 39,048